Analyst Rating Update on Organovo Holdings (ONVO)

Organovo Holdings (NYSEMKT:ONVO) : Zacks Investment Research ranks Organovo Holdings (NYSEMKT:ONVO) as 3, which is a Hold recommendation. 2 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. The average broker rating of 2 research analysts is 1, which indicates as a Strong Buy.

For the current week, the company shares have a recommendation consensus of Buy.

Organovo Holdings (NYSEMKT:ONVO): stock turned positive on Tuesday. Though the stock opened at $3.25, the bulls momentum made the stock top out at $3.44 level for the day. The stock recorded a low of $3.17 and closed the trading day at $3.36, in the green by 8.39%. The total traded volume for the day was 1,212,998. The stock had closed at $3.1 in the previous days trading.

In an insider trading activity,The director of Organovo Holdings, Inc., Baltera Robert Jr. sold 6,000 shares at $4.03 on September 21, 2015. The Insider selling transaction had a total value worth of $24,180. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.

Organovo Holdings, Inc. is a commercial-stage company focused on developing and commercializing functional human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The Company focuses on the generation of three-dimensional (3D) human tissues, by utilizing its platform technology to create human tissue constructs in 3D that mimic native human tissue composition, architecture, and function. Its platform, NovoGen Bioprinters, is focused on multiple 3D bioprinting technologies. Its commercial tissue exVive3D Human Liver Tissue is designed to be used for predictive preclinical testing of drug compounds. It is developing 3D Human Kidney Tissue, which can be used for predictive preclinical testing of drug compounds.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.